Eflapegrastim

N/A

Report date: 2025/02/07 16:33:33

Base Information

Drug NameEflapegrastim
Drug Alias Nameeflapegrastim- xnstEflafegrastimLong-acting G-CSF analogue (Hanmi)RolontisRolvedon +[11] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionColony stimulating factor 3 receptor agonists
TargetsColony stimulating factor 3 receptor
Therapy Area/IndicationsSolid tumoursFebrile NeutropeniaNeutropenia +[5] 
Global Approved IndicationsFebrile NeutropeniaNeutropenia
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2021/03/18
Country/TerritoryCanadaUnited StatesPoland +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co LtdSpectrum PharmaceuticalsTabuk Pharmaceuticals +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursFebrile NeutropeniaNeutropenia +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG